ClinicalTrials.gg

Program

Drugs, Investigational

Also written as “Investigational drug”, “Investigational new drug, company code: BGG492” and “TimoD implant”.

Its studies are mostly in Keratosis, Actinic · Glaucoma · Burns · Glaucoma, Open-Angle · Nervous System Diseases, led by 7 companies.

Furthest: phase 3, since Jun 17, 202510 company-led studies, 3 open or runningNext primary completion: Dec 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
EyeD Pharma21 open or runningphase 2since Jun 17, 2025Mar 13, 2024Jan 2027phase 2 · NCT07036510
Novartis20 open or runningphase 2since Apr 23, 2009Apr 23, 2009none ahead
Pfizer20 open or runningphase 2since May 2, 2002May 2, 2002none ahead
Bristol-Myers Squibb10 open or runningphase 2since Jun 26, 2002Jun 26, 2002none ahead
Merck10 open or runningphase 3since Aug 25, 2000Aug 25, 2000none ahead
Skingenix11 open or runningphase 2since Feb 14, 2011Feb 14, 2011Dec 31, 2026phase 2 · NCT01297400
Sun Pharmaceutical Industries11 open or runningphase 1since Jul 22, 2026Jul 22, 2026Dec 2026phase 1 · NCT07729579

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 25, 2000First study: phase 3 study in Alzheimer DiseaseNew to MerckMerck · NCT00006187 · United States
  2. May 2, 2002Pfizer’s first study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to PfizerPfizer · NCT00034957 · United States
  3. May 8, 2002Phase 1 study in Multiple MyelomaPfizer · NCT00036140 · United States
  4. Jun 26, 2002Bristol-Myers Squibb’s first study: phase 2 study in Colorectal NeoplasmsNew to Bristol-Myers SquibbBristol-Myers Squibb · NCT00040391 · United States
  5. Apr 23, 2009Novartis’s first study: phase 2 study in SeizuresNew to NovartisNovartis · NCT00887861 · 37 enrolled · Germany
  6. Jun 15, 2010Phase 2 study in Nervous System DiseasesNovartis · NCT01147003 · 93 enrolled · United States, Bulgaria, Germany and more
  7. Feb 14, 2011Skingenix’s first study: phase 2 study in BurnsNew to SkingenixSkingenix · NCT01297400 · 60 planned · United States, Mexico
  8. Mar 13, 2024EyeD Pharma’s first study: phase 1 study in Glaucoma, Open-AngleNew to EyeD PharmaEyeD Pharma · NCT06321562 · 1 enrolled · Germany
  9. Jun 17, 2025Phase 2 study in GlaucomaEyeD Pharma · NCT07036510 · 42 planned · Panama
  10. Jul 22, 2026Sun Pharmaceutical Industries’ first study: phase 1 study in Keratosis, ActinicNew to Sun Pharmaceutical IndustriesSun Pharmaceutical Industries · NCT07729579 · 48 planned · United States

Ahead

  1. Dec 2026Primary completion: phase 1 study in Keratosis, ActinicSun Pharmaceutical Industries · NCT07729579
  2. Dec 31, 2026Primary completion: phase 2 study in BurnsSkingenix · NCT01297400
  3. Jan 2027Primary completion: phase 2 study in GlaucomaEyeD Pharma · NCT07036510

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07729579Keratosis, Actinic · United States1RecruitingSun Pharmaceutical IndustriesDec 202648
NCT07036510Glaucoma · Panama2RecruitingEyeD PharmaJan 202742
NCT06321562Glaucoma, Open-Angle · Germany1TerminatedEyeD PharmaJun 26, 20251
NCT01297400Burns · United States, Mexico2RecruitingSkingenixDec 31, 202660
NCT01147003Nervous System Diseases · United States, Bulgaria, Germany and more2CompletedNovartisSep 201193
NCT00887861Seizures · Germany2CompletedNovartisAug 201037
NCT00040391Colorectal Neoplasms · United States2TerminatedBristol-Myers Squibb
NCT00036140Multiple Myeloma · United States1CompletedPfizer
NCT00034957Carcinoma, Non-Small-Cell Lung · United States2CompletedPfizerOct 2002
NCT00006187Alzheimer Disease · United States3TerminatedMerckJun 2005

How it is read

Names in the registry

  • “Investigational drug”, 5 entries
  • “Investigational new drug, company code: BGG492”, 3 entries
  • “TimoD implant”, 2 entries
  • “Investigational Drug, MW-III”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.